---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000068"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:21:58.740329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q1 revenue up 85% to $67.8M; net loss narrows 65%

## Summary
- Total revenue $67.8M, +85% YoY; test volumes 23,245, +61% YoY.
- Testing revenue $56.0M (+69%); Biopharma and other $8.8M (vs $0.6M); product revenue $3.0M (-3%).
- GAAP net loss $14.5M, improved 65%; diluted EPS loss $0.20, improved 70%.
- Non-GAAP gross margin 65%, roughly flat; cash $163.6M at quarter-end.
- Business highlights: expanded Percepta data at ATS, three AUA abstracts, launch of Biopharma Atlas.

## SEC filing metadata
- accession: 0001384101-22-000068
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/0001384101-22-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000068/vcyt-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000068
- JSON: https://secwatch.observer/filing/0001384101-22-000068.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.